Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
36
SCL Quote, Financials, Valuation and Earnings
Last price:
$64.80
Seasonality move
:
6.68%
Day range:
$66.33 - $67.34
52-week range:
$66.19 - $95.62
Dividend yield:
2.25%
P/E ratio:
33.37x
P/S ratio:
0.70x
P/B ratio:
1.24x
Volume:
167.3K
Avg. volume:
117.7K
1-year change:
-29.52%
Market cap:
$1.5B
Revenue:
$2.3B
EPS (TTM):
$2.01
Analysts' Opinion
-
Consensus RatingStepan has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $100.50, Stepan has an estimated upside of 44.6% from its current price of $67.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing 100% downside risk from its current price of $67.08.
Fair Value
-
According to the consensus of 2 analysts, Stepan has 44.6% upside to fair value with a price target of $100.50 per share.
SCL vs. S&P 500
-
Over the past 5 trading days, Stepan has underperformed the S&P 500 by -3.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Stepan does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Stepan revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Stepan reported revenues of $546.8M.
Earnings Growth
-
Stepan has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Stepan reported earnings per share of $1.03.
Enterprise value:
2.1B
EV / Invested capital:
1.07x
Price / LTM sales:
0.70x
EV / EBIT:
32.37x
EV / Revenue:
0.94x
PEG ratio (5yr expected):
--
EV / Free cash flow:
69.65x
Price / Operating cash flow:
52.26x
Enterprise value / EBITDA:
11.78x
Gross Profit (TTM):
$281.9M
Return On Assets:
1.94%
Net Income Margin (TTM):
2.1%
Return On Equity:
3.79%
Return On Invested Capital:
2.45%
Operating Margin:
4.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.4B | $2.2B | $562.2M | $546.8M | |
| Gross Profit | $442.6M | $279M | $281.9M | $71.2M | $75.7M | |
| Operating Income | $220.5M | $76.1M | $72M | $25.1M | $23.9M | |
| EBITDA | $318.2M | $170.3M | $174M | $51.4M | $52M | |
| Diluted EPS | $6.63 | $2.27 | $2.01 | $0.55 | $1.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $833M | $839.2M | $1.1B | $849.4M | $918.2M | |
| Total Assets | $1.6B | $2B | $2.3B | $2.3B | $2.4B | |
| Current Liabilities | $361.2M | $491.1M | $603.2M | $582.1M | $721.3M | |
| Total Liabilities | $678.4M | $896.9M | $1.2B | $1.1B | $1.2B | |
| Total Equity | $939.2M | $1.1B | $1.1B | $1.2B | $1.2B | |
| Total Debt | $207.9M | $279.8M | $564.9M | $649.4M | $688.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $125.7M | $191.7M | $162.7M | $70.1M | $22.7M | |
| Cash From Investing | -$282.7M | -$308.1M | -$127.5M | -$53.7M | -$26.7M | |
| Cash From Financing | $228.9M | $48.3M | $3.6M | -$41.3M | $22.9M | |
| Free Cash Flow | -$154.6M | -$118.1M | $29.4M | $16.4M | -$4M | |
SCL
Sector
Market Cap
$1.5B
$18.9M
Price % of 52-Week High
70.15%
57.75%
Dividend Yield
2.25%
0%
Shareholder Yield
--
1.61%
1-Year Price Total Return
-29.52%
-18.81%
Beta (5-Year)
0.822
1.063
Dividend yield:
2.25%
Annualized payout:
$1.47
Payout ratio:
73.49%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$68.61
200-day SMA
Sell
Level
$80.34
Bollinger Bands (100)
Sell
Level
71.89 - 77.35
Chaikin Money Flow
Buy
Level
13.6M
20-day SMA
Sell
Level
$72.65
Relative Strength Index (RSI14)
Sell
Level
26.66
ADX Line
Sell
Level
30.96
Williams %R
Buy
Level
-92.3173
50-day SMA
Sell
Level
$74.26
MACD (12, 26)
Sell
Level
-2.29
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0497)
Buy
CA Score
(Annual)
Level (0.0217)
Buy
Beneish M-Score
(Annual)
Level (-2.6072)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.2415)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. Surfactants are chemical agents that affect the interaction between two surfaces. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. Majority of Stepan's revenue comes from the United States.
Stock Forecast FAQ
In the current month, SCL has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The SCL average analyst price target in the past 3 months is $100.50.
-
Where Will Stepan Stock Be In 1 Year?
According to analysts, the consensus estimate is that Stepan share price will rise to $100.50 per share over the next 12 months.
-
What Do Analysts Say About Stepan?
Analysts are divided on their view about Stepan share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Stepan is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Stepan's Price Target?
The price target for Stepan over the next 1-year time period is forecast to be $100.50 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is SCL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Stepan is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of SCL?
You can purchase shares of Stepan via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Stepan shares.
-
What Is The Stepan Share Price Today?
Stepan was last trading at $64.80 per share. This represents the most recent stock quote for Stepan. Yesterday, Stepan closed at $67.08 per share.
-
How To Buy Stepan Stock Online?
In order to purchase Stepan stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.86% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 3.89% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.7% over the past day.
